image credit: Adobe Stock

FDA grants EUA for Lucira Health’s COVID-19 & Flu Test

November 23, 2022

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Lucira Health’s COVID-19 & Flu Test for use in point-of-care settings.

The nucleic acid amplification test (NAAT)/molecular test has been developed for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B viral RNA.

It uses a single anterior nasal swab sample collected from people aged two years and above, who are suspected of having a respiratory viral infection by their healthcare provider, to test for Covid-19 and all its variants of concern as well as Flu A and Flu B.

Read More on Medical Device Network